Daniel Ketelhuth

Daniel Ketelhuth

Principal Researcher | Docent
Visiting address: BioClinicum,plan 8, Karolinska universitetssjukhuset Solna, 17176 Stockholm
Postal address: K2 Medicin, Solna, K2 Kardiov m Olofsson P Gisterå A, 171 77 Stockholm

About me

  • Assoc. Professor of Experimental Cardiology
    ​1999 Biochemical-pharmacist - Faculty
    of Pharmaceutical Sciences, University of São Paulo (USP), Riberião Preto,
    2005 PhD in immunology. Institute of
    Biomedical Sciences, University of São Paulo (USP), São Paulo, Brazil.
    2005 – 2010 Postdoctoral fellow, Experimental Cardiovascular
    Research Unit, CMM, Karolinska University Hospital, Stockholm, Sweden.


  • Cardiovascular diseases (CVDs) are the leading cause of mortality and
    disability worldwide, imposing a significant burden on society. Coronary
    heart disease and cerebrovascular disease, the two most common forms of
    cardiovascular disease, are caused by acute complications of atherosclerosis.
    CVD kills over 17 million individuals every year, which accounts for one
    third of all global deaths.
    Although population-wide management of traditional risk factors for CVDs
    (e.g. hyperlipidemia, high-blood pressure, glycaemia) has reduced the
    incidence of cardiovascular events in developed countries, substantial
    residual risk remains. Thus, translational therapeutic strategies targeting
    novel molecular pathways regulating atherosclerosis are needed.
    Atherosclerosis is a chronic inflammatory disease initiated by retention and
    accumulation of lipids in the artery wall, especially low-density lipoprotein
    (LDL), leading to maladaptive responses of innate and adaptive immune cells.
    Notably, metabolism and activation are fully integrated in immune cells, and
    systemic or microenvironmental changes in metabolism have been shown to
    modulate their responses.
    In pioneer work, we have identified several targets to modulate the unwanted
    immune responses in the artery wall, including components of LDL that can
    trigger innate and adaptive immune cells, and metabolites of the essential
    amino acid tryptophan, via the Kynurenine pathway. Our research indicates
    that metabolites are not just ‘fuels’ in their metabolic pathways, but
    that they can also act as signalling molecules in immune cells and influence
    atherosclerosis. By increasing the understanding of the immunometabolic
    reactions controlling immune responses in atherogenesis, our research will
    lead to the development of new drugs to treat and prevent atherosclerotic
    *Selected publications*


All other publications


  • Principal Researcher, Department of Medicine, Karolinska Institutet, 2022-2024

Degrees and Education

  • Docent, Karolinska Institutet, 2017

News from KI

Events from KI